Neurolysin (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Neurolysin (NLN; UniProt Q9BYT8), expressed in HEK293 cells. Zinc metallopeptidase EC 3.4.24.16 suited for oligopeptide cleavage assays, inhibitor profiling, and antibody validation studies.
Expression system
HEK293
Cat. #
REC-Neurolysin

In stock

SKU
REC-Neurolysin
$498.00

Target Overview

Neurolysin (NLN; UniProt Q9BYT8) is a zinc-dependent metalloendopeptidase of the M3 family (EC 3.4.24.16), encoded by the NLN gene and localised to the mitochondrial intermembrane space in human cells. The full-length human sequence spans 704 amino acids. This recombinant form is produced in HEK293 mammalian cells, providing post-translational processing and folding conditions relevant to the native human enzyme — an important consideration for metallopeptidase activity assays where correct zinc coordination and tertiary structure directly affect catalytic output. Neurolysin cleaves oligopeptides at defined sites, with characterised substrates including neurotensin, bradykinin, and dynorphin A. It has also been described as a regulator of the cannabinoid signalling pathway through degradation of hemopressin, an endogenous antagonist of cannabinoid receptor CNR1. These substrate relationships make recombinant Neurolysin suitable for fluorogenic peptide cleavage assays, kinetic parameter determination (Km, kcat), and inhibitor IC50 measurements under defined in-vitro conditions. Because the protein is produced in a mammalian expression system, it is appropriate as a positive-control antigen in Western blot and immunohistochemistry antibody validation workflows. Researchers requiring a matched immunoreagent can pair this recombinant with Triple Point Biologics' RP-Neurolysin antibody, which has been validated against human NLN and carries predicted cross-reactivity to mouse, rat, and several other species. The recombinant is further applicable to binding assays, surface plasmon resonance, and pull-down experiments designed to identify NLN-interacting proteins or small-molecule binders.

Background

Neurolysin (NLN) is a mitochondrial zinc metallopeptidase that belongs to the M3 family of endopeptidases, a group defined by the conserved HEXXH zinc-binding motif. Its canonical substrates — neurotensin, bradykinin, and dynorphin A — are bioactive oligopeptides with roles in nociception, vasodilation, and neuromodulation, placing NLN at an enzymatic intersection relevant to multiple physiological systems. In addition to its classical neuropeptide-processing activity, NLN has been characterised as a regulator of cannabinoid signalling through proteolytic inactivation of hemopressin, an endocannabinoid-system peptide that acts as a CNR1 inverse agonist. This broader substrate profile has sustained interest in NLN as a tool enzyme for mapping peptide degradation pathways in cell-free and cell-based systems. In cancer biology, NLN has been studied as a research target in the context of lung cancer. Liu L et al. (2025, Redox Biol) reported that loss of NLN suppresses lung cancer progression by inducing ferroptosis through downregulation of m6A methylation of GPX4, identifying NLN as a node connecting RNA epitranscriptomic regulation to redox-mediated cell death. This published finding positions recombinant NLN as a useful reagent for researchers investigating the intersection of metallopeptidase activity, m6A modification, and ferroptosis pathways, including assays designed to probe how NLN expression levels affect downstream GPX4 abundance and oxidative stress tolerance in tumour cell models. Beyond oncology models, NLN's mitochondrial localisation has made it a subject of interest in studies of mitochondrial peptide homeostasis — the process by which organellar peptides generated during protein turnover are processed and cleared. Recombinant NLN produced in a mammalian system enables in-vitro reconstitution of these cleavage events under physiologically relevant conditions, supporting mechanistic dissection that is difficult to achieve with endogenous enzyme purified from tissue. Triple Point Biologics has supported proteinase and inhibitor research with antibody and recombinant protein reagents since 1994. This recombinant NLN preparation is intended for research use only and is not for diagnostic or therapeutic application. Researchers performing antibody validation — including Western blot titration and immunohistochemistry optimisation — can cross-reference the matched RP-Neurolysin antibody available in the Triple Point Biologics catalog.

Applications

  • Fluorogenic oligopeptide cleavage assay (e.g., neurotensin or bradykinin substrate)
  • Inhibitor IC50 determination by competitive activity assay
  • Kinetic parameter measurement (Km, kcat, kcat/Km) under defined buffer conditions
  • Antibody validation positive control for Western blot alongside RP-Neurolysin antibody
  • Immunohistochemistry antigen standard for RP-Neurolysin antibody optimisation
  • Pull-down or co-immunoprecipitation bait to identify NLN-interacting proteins
  • Surface plasmon resonance or biolayer interferometry binding assay for small-molecule NLN binders
  • Substrate identification by mass spectrometry using recombinant NLN as the test protease

References

  1. Liu L et al. Loss of NLN suppresses lung cancer progression by inducing ferroptosis through downregulating m(6)A methylation of GPX4. Redox Biol. 2025. doi:10.1016/j.redox.2025.103928. PMID: 41242017.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What is the expected molecular weight of recombinant Neurolysin on SDS-PAGE and Western blot?

The full-length human Neurolysin (UniProt Q9BYT8) is 704 amino acids, giving a predicted molecular weight of approximately 78 kDa. On reducing SDS-PAGE, this HEK293-expressed recombinant typically resolves as a single band at ~78–80 kDa. Minor upward shift relative to the calculated MW is common due to glycosylation or incomplete denaturation of the zinc-coordinated tertiary structure. Purity is >90% by SDS-PAGE. When using this recombinant as a Western blot positive control alongside RP-Neurolysin, expect the primary band at ~78–80 kDa.

Is this recombinant Neurolysin the full-length sequence or a processed mitochondrial form?

This recombinant is produced from the full-length 704-amino-acid human NLN sequence in HEK293 cells. Native Neurolysin contains an N-terminal mitochondrial targeting sequence (approximately residues 1–29) that is cleaved upon mitochondrial import in vivo. The HEK293 expression system may produce a mixture of processed and unprocessed forms depending on construct design — check the certificate of analysis for the specific construct boundaries used in your lot. If isoform resolution is critical for your experiment, the matched antibody RP-Neurolysin can help confirm the processed band by Western blot.

What substrates does recombinant Neurolysin cleave and which is best for a fluorogenic activity assay?

Neurolysin (EC 3.4.24.16) cleaves oligopeptides including neurotensin, bradykinin, dynorphin A, and hemopressin. For fluorogenic peptide cleavage assays, internally quenched fluorescent neurotensin analogs (e.g., Mca-Pro-Leu-Gly-Pro-D-Lys(Dnp)-OH) are the most widely used substrates and give robust signal-to-noise ratios. Substrate concentrations of 10–50 µM in assay buffer are a practical starting range. Hemopressin is the preferred substrate when studying cannabinoid receptor CNR1 signalling contexts, as Neurolysin's degradation of this endocannabinoid ligand is the relevant physiological endpoint.

What buffer conditions are recommended for Neurolysin activity assays with this recombinant?

The storage buffer for this recombinant is 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2 — the CaCl2 inclusion is standard for TPB metalloproteinase preparations to support zinc coordination. For activity assays, a working buffer of 50 mM HEPES or Tris-HCl pH 7.4, 150 mM NaCl, 1 mM ZnCl2 is compatible with published Neurolysin kinetic studies. Avoid strong chelators such as EDTA or EGTA, which strip the catalytic zinc and abolish activity. DTT at concentrations above 1 mM can also interfere; keep reducing agents minimal in the assay well.

What starting enzyme concentration should I use for a Neurolysin kinetic or inhibitor IC50 assay?

For initial kinetic characterisation, 1–10 nM recombinant Neurolysin in the assay well is a reasonable starting range with fluorogenic neurotensin substrates at 10–50 µM. For inhibitor IC50 determinations, use the lowest enzyme concentration that gives a reliable linear signal over your measurement window — typically 2–5 nM — to avoid substrate depletion artifacts and to ensure you are measuring true inhibitor potency rather than stoichiometric titration of active sites. Titrate the enzyme against your specific substrate lot before committing to a full inhibitor screen, as activity can vary between preparations.

Can I use recombinant Neurolysin as a positive control for Western blot with the RP-Neurolysin antibody?

Yes — this recombinant is the recommended positive control for the matched antibody RP-Neurolysin (/anti-neurolysin-rabbit-polyclonal-antibody). Both are produced in the same lab, so epitope compatibility is confirmed rather than inferred. Load 20–50 ng of recombinant Neurolysin per lane on a 10% SDS-PAGE gel alongside your cell lysates. The rabbit polyclonal detects the ~78–80 kDa band under standard reducing conditions. This pairing is particularly useful for antibody validation experiments and for confirming knockdown or overexpression in NLN-edited cell lines, where you need an unambiguous reference band.

How much recombinant Neurolysin should I load for a Western blot positive control lane?

20–50 ng per lane is the standard loading range for a clean, non-saturating signal with RP-Neurolysin on a standard chemiluminescent Western blot. At 50 ng, the ~78–80 kDa band is clearly visible without blooming into adjacent lanes. If you are running a quantitative Western or using near-infrared fluorescent secondary detection, start at 10–20 ng to stay within the linear dynamic range. Dilute the recombinant directly into 1× Laemmli sample buffer immediately before loading; do not pre-dilute in water, as diluting below the glycerol-buffered formulation can affect band sharpness.

How should I store and handle recombinant Neurolysin to preserve enzymatic activity long-term?

Store at −20°C in the single-use aliquots as supplied. The formulation — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2 — is designed for long-term stability at this temperature. Repeated freeze-thaw cycles progressively reduce metalloendopeptidase activity through zinc loss and aggregation; once an aliquot is thawed, use it the same day. If you need working dilutions, prepare them in assay-compatible buffer containing 0.1% BSA to reduce adsorptive losses at low protein concentrations (below ~50 ng/µL). Avoid metal-chelating plasticware additives and ensure all tips and tubes are low-binding grade.

Validation imagery coming soon

Western blot validation figures for REC-Neurolysin will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →